Next Meetings

Abuse-Deterrent Opioids

New England CEPAC

ICER will develop a report reviewing the clinical effectiveness and value of abuse-deterrent opioids. The report will be the subject of a July 20, 2017 meeting of the New England CEPAC.

The live webcast is available here: http://www.bizvision.com/webcast/prod/84251

Register or Register for the Live Webcast

Ovarian Cancer

Midwest CEPAC
September 14, 2017 10AM-4PM (CT)

University of Missouri-St. Louis
1 University Boulevard
St. Louis, MO 63121

The Midwest CEPAC will convene to discuss the findings of ICER's report on the comparative clinical effectiveness and value of treatment for ovarian cancer.

Register or Register for the Live Webcast

October 19, 2017 TBD

California TBD

ICER will review evidence on the comparative clinical effectiveness and value of certain cognitive and mind-body interventions for chronic low back and neck pain.


Tardive Dyskinesia

New England CEPAC
December 5, 2017 10am-4pm ET

Voretigene Neparvovec

Midwest CEPAC
January 25, 2018 10am-4pm CT

TBD

The Midwest CEPAC will convene to deliberate on ICER's report on voretigene neparvovec.


March 2, 2018 10am-4pm PT

California, TBD

The California Technology Assessment Forum will convene to discuss evidence on CAR-T therapies.


past Meetings

May 2017
ICER

Orphan Drug Assessment and Pricing Summit

ICER is hosting a multi-stakeholder policy summit to discuss methods for assessing the value of new drugs for rare conditions. The summit will include discussion of how methods can be applied to recommend fair prices that reflect the value of orphan drugs to patients and the health system, to allow for broader insurance coverage for innovative new treatments.

Process for Public Comment
A Briefing Paper posted on May 10, 2017 (white paper below) informed during the pricing summit. Following the meeting, ICER will produce a Final Meeting Report and Proposed Framework Changes document outlining modifications to its assessment process when applied to treatments for rare conditions. This document will be open for public comment for 60 days. Dates reflected below are tentative and subject to change.


Jun 2016
CTAF

Diabetes Prevention Programs

The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), held a public meeting in June 2016 to discuss the comparative effectiveness and value of diabetes prevention programs.